Document is current
Any future updates will be listed below
-
Authors
Kulakova, Liudmila
Li, Kiki H.
Chiang, Austin W. T.
Schwoerer, Michael P.
Suzuki, Saori
Schoffelen, Sanne
Elkholy, Khadija H.
Chao, Kinlin L.
Shahid, Salman
Kumar, Bhoj
Murray, Nathan B.
Archer-Hartmann, Stephanie
Azadi, Parastoo
Voldborg, Bjørn G.
Marin, Alexander
Mariuzza, Roy A.
Andrianov, Alexander K.
Ploss, Alexander
Lewis, Nathan E.
Toth, Eric A.
Fuerst, Thomas R.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (T32GM007388, T32GM007388, R35 GM119850)
National Institutes of Health (R24GM137782, R01 AI132212, R01 AI132212, R01 AI168048, R01 AI132212, R01 AI132212)
Novo Nordisk Foundation (NNF20SA0066621, NNF20SA0066621)
- License Information
-
More Information
Article History
Received: 27 January 2025
Accepted: 12 May 2025
First Online: 11 June 2025
Competing interests
: Thomas Fuerst, Nathan Lewis, and Alexander Andrianov are shareholders of NeuImmune, Inc., a company which uses the geCHO platform for the development of vaccines and other biologic therapeutics. This company had no role in the design of the study, collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. These potential conflicts of interest have been disclosed and are managed by the University of Maryland. Eric Toth is one of the holders of the geCHO intellectual property licensed by NeuImmune, Inc. from the University of Maryland. He has disclosed those interests fully to the University of Maryland, and has in place an approved plan for managing any potential conflicts arising from this. The other authors have no conflicts of interest to report.
